Eliksa Therapeutics is a venture-backed biotechnology company with a proprietary cGMP production facility and a robust clinical pipeline addressing unmet medical needs in ocular and cardiovascular indications. Our lead candidate, ELK-003, is a novel multi-target biological modulating inflammation, cell recovery, and tissue healing. ELK-003 has proven to be safe and well-tolerated with 18,000+ human doses without any reported side effects.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 3805 Old Easton Rd, Doylestown,pennsylvania 18902,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.eliksa.com
- HQ
- Doylestown, Pennsylvania
Eliksa Therapeutics Questions
Eliksa Therapeutics's website is http://www.eliksa.com
Eliksa Therapeutics's LinkedIn profile is https://www.linkedin.com/company/eliksa
Eliksa Therapeutics has
6 employees.
View email and phone details for 6
employees at Eliksa Therapeutics.
Eliksa Therapeutics's industry is
Biotechnology Research
Eliksa Therapeutics's top competitors are
Realize Therapeutics,
Stelexis Biosciences, Inc.,
Hula Therapeutics,
Tantigen Bio,
Pennsylvania Biotechnology Center,
Novira Therapeutics,
Verismo Therapeutics,
Fekra Therapeutics,
Thirdlaw Molecular,
Vigeo Therapeutics.
Eliksa Therapeutics's categories are Biotechnology Research
Eliksa Therapeutics's founding year is 2021
